Hydrocodone chemical structure
Find information on thousands of medical conditions and prescription drugs.

Hydrocodone

Hydrocodone or dihydrocodeinone (marketed as Vicodin, Anexsia, Dicodid, Hycodan, Hycomine, Lorcet, Lortab, Norco, Tussionex, Vicoprofen) is an opioid derived from either of the naturally occurring opiates codeine or thebaine. Hydrocodone is an orally active narcotic analgesic and antitussive. The typical therapeutic dose of 5 to 10 mg is pharmacologically equivalent to 30 to 60 mg of oral codeine. Sales and production of this drug have increased significantly in recent years, as have diversion and illicit use. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Hydrocodone is commonly available in tablet, capsule and syrup form.

As a narcotic, hydrocodone relieves pain by binding to opioid receptors in the brain and spinal cord. It may be taken with or without food, but should never be combined with alcohol. It may interact with monoamine oxidase inhibitors, as well as other drugs that cause drowsiness. It is in FDA pregnancy category C: its effect on an unborn embryo or fetus is not clearly known and pregnant women should consult their physicians before taking it. Common side effects include dizziness, lightheadedness, nausea, drowsiness, euphoria, vomiting, and constipation. Some less common side effects are allergic reaction, blood disorders, changes in mood, mental fogginess, anxiety, lethargy, difficulty urinating, spasm of the ureter, irregular or depressed respiration and rash.

Hydrocodone can be habit-forming, and can lead to physical and psychological addiction. In the U.S., pure hydrocodone and forms containing more than 15 mg per dosage unit are considered Schedule II drugs. Those containing less than 15 mg per dosage unit are Schedule III drugs. Hydrocodone is typically found in combination with other drugs such as paracetamol (acetaminophen), aspirin and homatropine methylbromide. In the UK it is listed as a Class A drug under the Misuse of Drugs Act 1971.

The presence of acetaminophen in hydrocodone-containing products deters many drug users from taking excessive amounts. However, some users will get around this by extracting a portion of the acetaminophen using hot/cold water, taking advantage of the water-soluble element of the drug. It is not uncommon for addicts to have liver problems from taking excessive amounts of acetaminophen over a long period of time--taking 10–15 grams of acetaminophen in a period of 24 hours typically results in severe hepatotoxicity. It is this factor that leads many addicts to use only single entity opiates such as OxyContin.

Symptoms of hydrocodone overdosage include respiratory depression, extreme somnolence, coma, stupor, cold/clammy skin, sometimes bradycardia, and hypotension. A severe overdose may involve circulatory collapse, cardiac arrest and/or death.

Notes

  1. ^  Tarascon Pocket Pharmacopoeia.

Read more at Wikipedia.org


[List your site here Free!]


Tramadol Or Hydrocodone-Acetaminophen For Acute Musculoskeletal Pain?
From Journal of Family Practice, 11/1/98 by Robert C. Marshall

Turturro MA, Paris PM, Larkin GL. Tramadol versus hydrocodone-acetaminophen in acute musculoskeletal pain: a randomized, double-blind clinical trial. Ann Emerg Med 1998; 32:139-43.

Clinical question Is tramadol (Ultram) equivalent to a hydrocodone-acetaminophen combination in the treatment of acute musculoskeletal pain?

Background Tramadol is a centrally acting oral analgesic that has both mild opioid activity and monoamine reuptake inhibition. Indicated primarily for the treatment of chronic pain, it has been marketed extensively to providers who manage acute pain, because it has a low potential for abuse and no antiprostaglandin side effects. While it has been studied in comparison with other analgesics for postoperative pain, there have been no studies looking at comparable efficacy for acute outpatient pain management.

Population studied The authors studied a convenience sample of 68 adult patients, aged 18 to 70 years, presenting to the emergency department (ED) with acute musculoskeletal pain secondary to trauma. Exclusion criteria included having taken an analgesic within 4 hours of arrival to the ED, pregnancy, lactation, acute intoxication, suspected substance abuse, and a history of sensitivity to tramadol hydrochloride or either component of hydrocodone with acetaminophen. Patients taking monoamine oxidase inhibitors, carbamazepine, quinidine, tricyclic compounds, or selective serotonin reuptake inhibitors were excluded because of potential drug interactions or risk of seizures. Patients with back pain, because of the complexity of both the pain and the therapy, and patients who the examining provider felt required parenteral analgesia, were also excluded. Because of the small sample size and the evaluation of acute pain syndromes exclusively of the musculoskeletal type, relevance to the usual outpatient practice of family physicians is questionable.

Study design and validity This is a randomized, prospective, double-blind, nonplacebo-controlled study comparing the analgesic effect of tramadol hydrochloride (100 mg) to hydrocodone (5 mg) with acetaminophen (500 mg) in acute musculoskeletal pain secondary to trauma. No placebo control group was used because of ethical concerns about withholding analgesics from patients with acute pain. The capsules given to each group were identical in appearance. Pain was evaluated at baseline and at 30, 60, 90, 120, and 180 minutes, using a 100-mm visual analog pain scale (VAS). To reduce carryover bias, patients were not allowed to view previously completed scales when completing a new one. A power analysis showed that the number of patients enrolled was adequate to ensure a 90% probability that a VAS score difference of 30% was not because of random chance. All comparisons between groups used intention-to-treat analysis correctly. All other statistical tests were appropriate. The dropout rate was less than 10% for each group.

Outcomes measured The primary outcome measured was the interval level of pain using the VAS. Side effects were also elicited through open-ended questioning at the end of each subject's study period.

Results Sixty-eight subjects were enrolled in the study. Six patients, 3 from each group, dropped out because of insufficient analgesia (P = ns). The discharge diagnoses were similar between groups, and included 19 distal extremity fractures, 26 sprains or strains, and 21 contusions. Mean pain scores were similar at baseline and improved in both groups throughout the study interval. Mean pain scores in the hydrocodone-acetaminophen group were significantly lower than the tramadol group at 30 minutes (51 vs 63, P = .03), and the difference became more pronounced with each successive interval (180 minutes: 23 vs 51, P [is less than] .01). Six patients in the tramadol group and 4 patients in the hydrocodone-acetaminophen group exhibited side effects, with nausea or vomiting, drowsiness or dizziness, and anxiety reported.

Recommendations for clinical practice Compared with hydrocodone-acetaminophen, tramadol is an inferior acute pain analgesic for the treatment of acute musculoskeletal pain due to trauma. Tramadol's manufacturer has reported a significant side-effect profile, with almost 25% of patients reporting dizziness, nausea, and constipation, and nearly 20% reporting headache or somnolence. Given the significant cost differential between tramadol and hydrocodone-acetaminophen and taking into account tramadol's side-effect profile, unless there is some overriding reason to use tramadol, it should be considered a second-line agent in this setting. Studies comparing tramadol with other less expensive analgesics for both acute and chronic pain in the primary care setting are needed.

COPYRIGHT 1998 Dowden Health Media, Inc.
COPYRIGHT 2004 Gale Group

Return to Hydrocodone
Home Contact Resources Exchange Links ebay